Bio-Rad Laboratories (BIO) AI Stock Analysis

• Market Cap: $7.21B
• Dividend Yield: N/A
• Average Volume (3M): 306.80K
• Price to Earnings (P/E): 22.5
• Beta (1Y): 0.85
• Revenue Growth: -0.33%
• EPS Growth: N/A
• Country: US
• Employees: 7,700
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): 2.61
• Shares Outstanding: 21,992,308
• 10 Day Avg. Volume: 421,224
• 30 Day Avg. Volume: 306,797
• PEG Ratio: -0.03
• Price to Book (P/B): 1.41
• Price to Sales (P/S): 3.61
• P/FCF Ratio: 34.82
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 2.58
• Enterprise Value/Gross Profit: 4.89
• Enterprise Value/Ebitda: 9.62
• 1Y Price Target: $333.00
• Price Target Upside: 22.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 59 Neutral
• Price Target: $297.00 ▲(9.12% Upside)

Bio-Rad Laboratories' overall stock score reflects significant financial challenges but potential growth opportunities. The financial performance is the most critical factor, indicating underlying risks due to declining revenues and net losses. However, technical indicators and recent corporate events show positive momentum, while strategic advancements highlighted in the earnings call bolster future prospects.

Positive Factors

Cash Flow Management

The CFO is targeting a significant increase in free cash flow by improving terms with suppliers and employing lean methods to reduce inventories.

Operational Strategy

New operational leaders are emphasizing cost efficiencies and prioritizing high-growth areas.

Negative Factors

Growth Forecast

The price target for Bio-Rad Laboratories has been lowered from $260 to $245 due to revised assumptions for growth.

Operating Margins

Operating profit margins were lowered to 10-12% vs. 13-15% prior.

Policy Impact

Bio-Rad Laboratories is expected to experience lower growth in their Life Sciences segment due to recent US policy changes and uncertainty around NIH funding.

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

How the Company Makes Money

Bio-Rad Laboratories generates revenue primarily through the sale of its life science research and clinical diagnostics products. The Life Science segment offers tools for cell biology research, gene expression analysis, protein purification, and various other applications, contributing significantly to the company's revenue. The Clinical Diagnostics segment provides products and systems for blood testing, diabetes monitoring, autoimmune testing, and other diagnostics, which are used in hospital laboratories, reference laboratories, transfusion laboratories, and physician office laboratories. Bio-Rad also earns from service contracts, training, and the sale of replacement parts for its instruments. The company benefits from strategic partnerships and collaborations with academic institutions and industry players, enhancing its product offerings and market reach. Additionally, Bio-Rad invests in research and development to drive innovation and maintain its competitive edge in the market.

Bio-Rad Laboratories Financial Statement Overview

Summary

Bio-Rad Laboratories faces financial challenges with declining revenues and net losses affecting profitability. Despite a conservative leverage position, the company struggles with negative ROE and inconsistent cash flow growth, indicating underlying risks. Stability in cash generation is a positive but operational inefficiencies must be addressed.

Income Statement

Bio-Rad Laboratories has experienced significant challenges in its profitability metrics. The TTM gross profit margin stands at approximately 53.86%, which is reasonable. However, the net profit margin is deeply negative due to substantial net losses, marking a concerning trend. The revenue has been declining, with a negative growth rate over the recent periods, indicating shrinking sales. EBIT and EBITDA margins are also under pressure, with EBITDA being negative, highlighting operational inefficiencies.

Balance Sheet

The balance sheet of Bio-Rad Laboratories shows mixed signals. The debt-to-equity ratio is low, indicating a conservative leverage position, which is a positive aspect. However, the equity ratio has been declining, which suggests a reduction in equity relative to total assets. ROE is negative due to net losses, which is a critical weakness. Overall, while leverage is under control, the negative ROE poses risks to financial stability.

Cash Flow

Bio-Rad Laboratories' cash flow profile presents both strengths and challenges. The operating cash flow to net income ratio is positive, indicating that the company is generating cash from its operations despite net losses. However, free cash flow growth has been inconsistent, with recent periods showing declines, which could affect future investments and financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.55B	2.57B	2.67B	2.80B	2.92B	2.55B
Gross Profit	1.35B	1.38B	1.43B	1.57B	1.64B	1.44B
EBITDA	686.19M	-2.14B	-654.80M	-4.49B	5.59B	5.08B
Net Income	319.17M	-1.84B	-637.32M	-3.63B	4.25B	3.81B
Balance Sheet
Total Assets	10.21B	9.36B	12.30B	13.50B	17.80B	12.97B
Cash, Cash Equivalents and Short-Term Investments	1.37B	1.66B	1.61B	1.79B	869.92M	991.12M
Total Debt	1.41B	1.37B	1.41B	1.39B	223.38M	225.74M
Total Liabilities	3.09B	2.79B	3.56B	3.89B	4.11B	3.09B
Stockholders Equity	7.13B	6.57B	8.74B	9.62B	13.69B	9.88B
Cash Flow
Free Cash Flow	347.52M	266.20M	218.26M	80.29M	535.72M	476.41M
Operating Cash Flow	534.16M	455.20M	374.94M	194.45M	669.46M	584.97M
Investing Cash Flow	-198.68M	-160.20M	20.21M	-1.21B	-797.38M	-69.89M
Financing Cash Flow	-356.23M	-218.80M	-425.65M	973.58M	-55.43M	-523.04M

Bio-Rad Laboratories Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 272.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Positive. The current price of 272.18 is above the 20-day moving average (MA) of 255.79, above the 50-day MA of 242.39, and below the 200-day MA of 285.30, indicating a neutral trend. The MACD of 6.84 indicates Negative momentum. The RSI at 60.23 is Neutral, neither overbought nor oversold. The STOCH value of 72.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BIO.

Bio-Rad Laboratories Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRTC	66 Neutral	$5.15B	―	-91.13%	―	22.37%	31.14%
ITGR	65 Neutral	$3.77B	46.53	5.15%	―	7.21%	-23.29%
LIVN	61 Neutral	$2.32B	30.62	-17.87%	―	8.57%	-1154.64%
BIO	59 Neutral	$7.21B	22.53	4.59%	―	-0.33%	―
INSP	58 Neutral	$2.60B	50.93	8.07%	―	22.05%	785.52%
Sector *	50 Neutral	AU$2.60B	3.64	-58.14%	2.69%	36.37%	13.78%
BRKR	50 Neutral	$4.86B	66.28	4.43%	0.62%	10.36%	-78.26%

Bio-Rad Laboratories Corporate Events

Bio-Rad Reports Q2 2025 Financial Results

Bio-Rad Laboratories announced its financial results for the second quarter of 2025, reporting a 2.1% increase in total net sales compared to the same period in 2024, driven by higher sales in process chromatography products. The company completed the acquisition of Stilla Technologies, enhancing its Droplet Digital PCR offerings. Despite a slight decline in gross margin and income from operations, Bio-Rad recognized a significant net income due to changes in the fair market value of its investment in Sartorius AG. The company updated its full-year 2025 financial outlook, expecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent.

The most recent analyst rating on (BIO) stock is a Buy with a $400.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.

Bio-Rad Laboratories Appoints New Executive VP for Growth

Bio-Rad Laboratories announced the appointment of Rajat Mehta as Executive Vice President, Global Commercial Operations, effective August 4, 2025, following the retirement of Mike Crowley after a 26-year tenure. Mehta brings extensive leadership experience from Labcorp and Thermo Fisher Scientific, and his appointment is expected to drive Bio-Rad’s global commercial strategy and long-term growth, enhancing its position in the life science and clinical diagnostics markets.

The most recent analyst rating on (BIO) stock is a Buy with a $390.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.

Bio-Rad Completes Acquisition of Stilla Technologies

Bio-Rad Laboratories, Inc. announced on February 13, 2025, that it had entered into a binding offer to acquire all equity interests of Stilla Technologies, a French corporation. The acquisition was completed by an affiliate of Bio-Rad on June 30, 2025, marking a significant expansion of the company’s operations.

The most recent analyst rating on (BIO) stock is a Buy with a $390.00 price target. To see the full list of analyst forecasts on Bio-Rad Laboratories stock, see the BIO Stock Forecast page.